


**Supplementary Figure 1. Flow Diagram of Patient Enrollment and Exclusion**



**Supplemental Table 1. Biomarkers for predicting AKI progression: multivariate logistic regression analyses using the non-normalized data <sup>a</sup>**

Biomarker	Cut Points	N	AKI Progression (%)	Unadjusted OR (95%CI)	P	Adjusted OR <sup>b</sup> (95%CI)	P
<b>uAGT, ng/ml</b>							
Low (T1)	0.01-15.8	71	8.5	1 (referent)	<0.001	1 (referent)	<0.001
Medium (T2)	15.9-102.4	71	18.3	2.4 (0.9-6.8)		2.8 (0.9-8.5)	
High (T3)	>102.4	71	43.7	8.4 (3.2-21.9)		10.4 (3.6-30.9)	
<b>uNGAL, ng/ml</b>							
Low (T1)	0.1-30.1	71	9.9	1 (referent)	<0.001	1 (referent)	0.009
Medium (T2)	30.2-94.0	68	20.6	2.4 (0.9-6.3)		2.1 (0.7-6.0)	
High (T3)	>94	74	39.2	5.8 (2.3-14.6)		4.5 (1.7-11.9)	
<b>uIL-18, pg/ml</b>							
Low (T1)	1.4-16.4	70	14.3	1 (referent)	<0.001	1 (referent)	0.002
Medium (T2)	16.5-178.1	73	13.7	0.9 (0.4-2.5)		0.8 (0.3-2.1)	
High (T3)	>178.1	70	42.9	4.5 (2.0-10.2)		3.1 (1.3-7.6)	

<sup>a</sup> AKI progression is defined as worsening of AKI stage (from stage 1 to either stage 2 or 3 or from stage 2 to 3). Biomarkers are measured at the time of stage 1 or 2 AKI diagnosis.

<sup>b</sup> Adjusted for age, gender, hypertension, diabetes, pre-admission eGFR, NT-proBNP, serum albumin, hemoglobin, diuretic dosage before AKI, use of spironolactone before AKI, use of RAS inhibitors before AKI, and change of serum creatinine from baseline at the time of AKI diagnosis. Site is adjusted as a random effect.

**Abbreviations:** OR, odds ratio; T, tertile; RAS, renin-angiotensin system.

**Supplemental Table 2. Biomarkers for predicting AKI progression: multivariate logistic regression analysis using levels of the biomarkers as the continuous variables.**

Biomarkers	Unadjusted odds ratio	95%CI	P	Adjusted odds ratio	95%CI	P
uAGT, µg/g Cr	4.8	2.5-8.9	<0.001	4.7	2.3-9.6	<0.001
uNGAL, µg/g Cr	2.6	1.8-3.7	<0.001	2.8	1.8-4.5	<0.001
uIL-18, ng/g Cr	2.7	1.8-3.9	<0.001	2.4	1.6-3.7	<0.001

Results are presented as per SD increment in the log values, adjusted for age, gender, hypertension, diabetes, pre-admission eGFR, NT-proBNP, serum albumin, hemoglobin, diuretic dosage before AKI, use of spironolactone before AKI, use of RAS inhibitors before AKI, and change of serum creatinine from baseline at the time of AKI diagnosis

**Supplemental Table 3. Performance of urinary biomarkers for predicting AKI progression and/or death in total cohort**

Biomarkers	AUC	95%CI	P
uAGT	0.71	0.63-0.78	<0.001
uNGAL	0.70	0.62-0.77	<0.001
uIL-18	0.65	0.56-0.73	<0.001